Publications by authors named "Xixi Jing"
Plasma-Activated AVC Hydrogel for Reactive Oxygen and Nitrogen Species Delivery to Treat Allergic Contact Dermatitis.
ACS Appl Mater Interfaces
October 2024
Article Synopsis
- Allergic contact dermatitis (ACD) is a widespread inflammatory skin condition, making up about 20% of occupational skin diseases, and current treatments often fall short due to inflammation and bacterial infections.
- Cold atmospheric plasma therapy shows promise for ACD treatment but faces challenges like risks of burns and inadequate delivery of therapeutic agents.
- The study introduces plasma-activated AVC (PA-AVC) hydrogels that safely deliver plasma-generated therapeutic compounds, demonstrating effective reduction of ACD symptoms in lab tests without causing systemic toxicity.
Multiple RONS-Loaded Plasma-Activated Ice Microneedle Patches for Transdermal Treatment of Psoriasis.
ACS Appl Mater Interfaces
September 2024
Article Synopsis
- * Researchers have developed patches of plasma-activated ice microneedles (PA-IMNs) that can deliver reactive oxygen and nitrogen species (RONS) directly to the skin, targeting psoriasis more effectively than traditional CAP methods.
- * In studies with mice, PA-IMNs demonstrated significant anti-inflammatory effects and reduced keratinocyte overgrowth without causing systemic toxicity, suggesting a promising alternative for psoriasis treatment.
Malignant melanoma is the most lethal form of skin cancer. As a promising anti-cancer agent, plasma-activated water (PAW) rich in reactive oxygen and nitrogen species (RONS) has shown significant potential for melanoma treatment. However, rapid decay of RONS and inefficient delivery of PAW in conventional injection methods limit its practical applications.
View Article and Find Full Text PDFBackground: COVID-19 patients may experience "cytokine storm" when human immune system produces excessive cytokines/chemokines. However, it remains unclear whether early responses of inflammatory cytokines would lead to high or low titers of anti-SARS-CoV-2 antibodies.
Methods: This retrospective study enrolled a cohort of 272 hospitalized patients with laboratory-confirmed SARS-CoV-2.
Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study.
Aging (Albany NY)
December 2020
The COVID-19 pandemic causes severe morbidity and mortality. This multi-country study aimed to explore risk factors that drive mortality in COVID-19 patients who received neither dexamethasone nor remdesivir. We analyzed a cohort of 568 survivors and 507 non-survivors from China, European regions, and North America.
View Article and Find Full Text PDFOn June 8, 2018, an NS3/4A protease inhibitor called danoprevir was approved in China to treat the infections of HCV genotype (GT) 1b - the most common HCV genotype worldwide. Based on phase 2 and 3 clinical trials, the 12-week regimen of ritonavir-boosted danoprevir (danoprevir/r) plus peginterferon alpha-2a and ribavirin offered 97.1% (200/206) of sustained virologic response at post-treatment week 12 (SVR12) in treatment-naïve non-cirrhotic patients infected with HCV genotype 1b.
View Article and Find Full Text PDF